{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T06:27:13Z","timestamp":1787120833798,"version":"build-2736575974"},"reference-count":107,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Cyclin-dependent kinase 4 and 6 (CDK4\/6) inhibitors are established components of endocrine therapy for hormone receptor-positive (HR+), HER2-negative breast cancer. Beyond RB-dependent G1 arrest, these drugs alter antigen presentation, interferon signaling, checkpoint-ligand expression, suppressive immune-cell populations, and CD8+ T-cell fate. The direction and durability of these effects vary across tumors and treatment settings. Early combinations with immune checkpoint inhibitors (ICIs) have produced activity signals, but hepatotoxicity and pneumonitis have limited several regimens. Radiotherapy and antibody-drug conjugates (ADCs) offer different routes to antigen release and innate immune activation. Therapeutic vaccination and dendritic-cell support provide a further route to exploit treatment-induced antigen display, although this rationale remains preclinical. We examine CDK4\/6 inhibitors as conditional immune-priming agents whose value depends on baseline immune contexture, tumor-cell-cycle dependence, endocrine therapy, drug and dose, exposure duration, partner treatment, and organ reserve. Here, immune priming is an operational term for a treatment-induced immune state that a subsequent therapy may use; it does not imply proven\n                    <jats:italic>de novo<\/jats:italic>\n                    activation of na\u00efve T cells. Evidence is separated into clinical outcomes, human translational findings, preclinical mechanisms, and testable hypotheses. This synthesis supports a therapeutic-window strategy in which a defined exposure is assessed for a measurable immune change before treatment is escalated. The immediate translational challenge is to identify that window, determine when it can be exploited, and recognize when continued exposure is more likely to reinforce resistance or toxicity.\n                  <\/jats:p>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/clinicaltrials.gov\/study\/<\/jats:ext-link>\n                      ,identifier NCT05766410.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1934879","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T05:44:48Z","timestamp":1787118288000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["CDK4\/6 inhibitors as conditional immune-priming agents in breast cancer: therapeutic windows, sequencing strategies, and rational combinations with immunotherapy, radiotherapy, and antibody-drug conjugates"],"prefix":"10.3389","volume":"17","author":[{"given":"Chenhui","family":"Zheng","sequence":"first","affiliation":[{"name":"Department of Surgical Oncology, Taizhou Central Hospital (Taizhou University Hospital)","place":["Taizhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Taizhou Central Hospital (Taizhou University Hospital)","place":["Taizhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danni","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Taizhou Central Hospital (Taizhou University Hospital)","place":["Taizhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Taizhou Central Hospital (Taizhou University Hospital)","place":["Taizhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial","volume":"6","author":"Sledge","year":"2020","journal-title":"JAMA Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01994","article-title":"Adjuvant abemaciclib plus endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative, high-risk early breast cancer: Results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes","volume":"42","author":"Rastogi","year":"2024","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus endocrine therapy in early breast cancer","volume":"390","author":"Slamon","year":"2024","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc1495","article-title":"CDK4 and CDK6 kinases: from basic science to cancer therapy","volume":"375","author":"Fassl","year":"2022","journal-title":"Science"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nature23465","article-title":"CDK4\/6 inhibition triggers anti-tumour immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0915","article-title":"CDK4\/6 inhibition augments antitumor immunity by enhancing T-cell activation","volume":"8","author":"Deng","year":"2018","journal-title":"Cancer Discov"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.02.053","article-title":"The CDK4\/6 inhibitor abemaciclib induces a T cell inflamed tumor microenvironment and enhances the efficacy of PD-L1 checkpoint blockade","volume":"22","author":"Schaer","year":"2018","journal-title":"Cell Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nature25015","article-title":"Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance","volume":"553","author":"Zhang","year":"2018","journal-title":"Nature"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1554","article-title":"CDK4\/6 inhibition promotes antitumor immunity through the induction of T-cell memory","volume":"11","author":"Lelliott","year":"2021","journal-title":"Cancer Discov"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1540","article-title":"Inhibition of CDK4\/6 promotes CD8 T-cell memory formation","volume":"11","author":"Heckler","year":"2021","journal-title":"Cancer Discov"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20220729","article-title":"PD-1 blockade and CDK4\/6 inhibition augment nonoverlapping features of T cell activation in cancer","volume":"220","author":"Ali","year":"2023","journal-title":"J Exp Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104010","article-title":"Immune effects of CDK4\/6 inhibitors in patients with HR+\/HER2-negative metastatic breast cancer: Relief from immunosuppression is associated with clinical response","volume":"79","author":"Scirocchi","year":"2022","journal-title":"EBioMedicine"},{"key":"B16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejca.2021.05.035","article-title":"Phase I\/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer","volume":"154","author":"Yuan","year":"2021","journal-title":"Eur J Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41523-022-00482-2","article-title":"Abemaciclib in combination with pembrolizumab for HR+, HER2- metastatic breast cancer: Phase 1b study","volume":"8","author":"Rugo","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010430","article-title":"Phase I study of ribociclib (CDK4\/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer","volume":"13","author":"Garrido-Castro","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17243997","article-title":"The dual effects of CDK4\/6 inhibitors on tumor immunity","volume":"17","author":"Si","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032236","article-title":"Deciphering the immunomodulatory role of cyclin-dependent kinase 4\/6 inhibitors in the tumor microenvironment","volume":"24","author":"Pandey","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/08820139.2024.2304565","article-title":"Effect of CDK4\/6 inhibitors on tumor immune microenvironment","volume":"53","author":"Liu","year":"2024","journal-title":"Immunol Invest"},{"key":"B22","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","article-title":"Breast cancer: pathogenesis and treatments","volume":"10","author":"Xiong","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall survival with pembrolizumab in early-stage triple-negative breast cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","article-title":"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer","volume":"32","author":"Miles","year":"2021","journal-title":"Ann Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003171","article-title":"Role of Fc\u03b3 receptors in HER2-targeted breast cancer therapy","volume":"10","author":"Musolino","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13046-020-01788-4","article-title":"The immunomodulatory effects of endocrine therapy in breast cancer","volume":"40","author":"Huang","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1038\/s41467-025-58266-8","article-title":"Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)","volume":"16","author":"Tsao","year":"2025","journal-title":"Nat Commun"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.semcancer.2017.10.003","article-title":"Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: a report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer","volume":"52","author":"Dieci","year":"2018","journal-title":"Semin Cancer Biol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.3056","article-title":"Tumor-infiltrating lymphocytes in triple-negative breast cancer","volume":"331","author":"Leon-Ferre","year":"2024","journal-title":"JAMA"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-021-00911-1","article-title":"A single-cell and spatially resolved atlas of human breast cancers","volume":"53","author":"Wu","year":"2021","journal-title":"Nat Genet"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00527-w","article-title":"Immune landscape in invasive ductal and lobular breast cancer reveals a divergent macrophage-driven microenvironment","volume":"4","author":"Onkar","year":"2023","journal-title":"Nat Cancer"},{"key":"B41","doi-asserted-by":"publisher","first-page":"5668","DOI":"10.1038\/s41467-021-25962-0","article-title":"Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer","volume":"12","author":"Hammerl","year":"2021","journal-title":"Nat Commun"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1172\/JCI166740","article-title":"Breast cancer immunopeptidomes contain numerous shared tumor antigens","volume":"134","author":"Kina","year":"2024","journal-title":"J Clin Invest"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1916243","article-title":"Low-dose CDK4\/6 inhibitors induce presentation of pathway specific MHC ligands as potential targets for cancer immunotherapy","volume":"10","author":"Charles","year":"2021","journal-title":"Oncoimmunology"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.116676","article-title":"CDK4\/6 inhibition reprograms the breast cancer immunopeptidome via Rb-dependent chromatin and transcriptomic remodeling","volume":"44","author":"Minati","year":"2025","journal-title":"Cell Rep"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf2834","article-title":"CANCER IMMUNOLOGY. The \"cancer immunogram","volume":"352","author":"Blank","year":"2016","journal-title":"Science"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.22.012703.104803","article-title":"The three Es of cancer immunoediting","volume":"22","author":"Dunn","year":"2004","journal-title":"Annu Rev Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/s41523-025-00767-2","article-title":"Baseline cell cycle and immune profiles indicate CDK4\/6 inhibitor response in metastatic HR\u2009+\u2009\/HER2- breast cancer","volume":"11","author":"Tzetzo","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.764062","article-title":"Type III interferons: emerging roles in autoimmunity","volume":"12","author":"Manivasagam","year":"2021","journal-title":"Front Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.10.019","article-title":"STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors","volume":"41","author":"Deng","year":"2014","journal-title":"Immunity"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13541","article-title":"CDK4\/6 inhibitors induce breast cancer senescence with enhanced anti-tumor immunogenic properties compared with DNA-damaging agents","volume":"18","author":"Lee","year":"2024","journal-title":"Mol Oncol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"key":"B53","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/s41467-026-68570-6","article-title":"Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive\/HER2-negative breast cancer: a phase 2 trial","volume":"17","author":"Kong","year":"2026","journal-title":"Nat Commun"},{"key":"B54","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41389-023-00475-1","article-title":"CDK4\/6 inhibitors and the pRB-E2F1 axis suppress PVR and PD-L1 expression in triple-negative breast cancer","volume":"12","author":"Shrestha","year":"2023","journal-title":"Oncogenesis"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2522872123","article-title":"Regulation of the immune CD155-CD226-TIGIT axis by cyclin D-CDK4\/6","volume":"123","author":"Fassl","year":"2026","journal-title":"Proc Natl Acad Sci USA"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.03.010","article-title":"Mechanisms of sensitivity and resistance to CDK4\/6 inhibition","volume":"37","author":"\u00c1lvarez-Fern\u00e1ndez","year":"2020","journal-title":"Cancer Cell"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx784","article-title":"Polyclonal RB1 mutations and acquired resistance to CDK 4\/6 inhibitors in patients with metastatic breast cancer","volume":"29","author":"Condorelli","year":"2018","journal-title":"Ann Oncol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"5258","DOI":"10.1038\/s41467-022-32828-6","article-title":"High p16 expression and heterozygous RB1 loss are biomarkers for CDK4\/6 inhibitor resistance in ER-positive breast cancer","volume":"13","author":"Palafox","year":"2022","journal-title":"Nat Commun"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.08.011","article-title":"Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials","volume":"34","author":"Andr\u00e9","year":"2023","journal-title":"Ann Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.154402","article-title":"RB expression confers sensitivity to CDK4\/6 inhibitor-mediated radiosensitization across breast cancer subtypes","volume":"7","author":"Pesch","year":"2022","journal-title":"JCI Insight"},{"key":"B61","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.molcel.2019.01.004","article-title":"A code of mono-phosphorylation modulates the function of RB","volume":"73","author":"Sanidas","year":"2019","journal-title":"Mol Cell"},{"key":"B62","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.molcel.2018.10.034","article-title":"Phosphorylated RB promotes cancer immunity by inhibiting NF-\u03baB activation and PD-L1 expression","volume":"73","author":"Jin","year":"2019","journal-title":"Mol Cell"},{"key":"B63","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejca.2021.11.025","article-title":"Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer: findings from the RIBECCA trial","volume":"162","author":"Peuker","year":"2022","journal-title":"Eur J Cancer"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3390\/cimb44090292","article-title":"Clinico-immunological effects of a single-agent CDK4\/6 inhibitor in advanced HR+\/HER2-negative breast cancer based on a window of opportunity study","volume":"44","author":"D'Angelo","year":"2022","journal-title":"Curr Issues Mol Biol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3390\/cells13161391","article-title":"Effect of cyclin-dependent kinase 4\/6 inhibitors on circulating cells in patients with metastatic breast cancer","volume":"13","author":"Lobo-Martins","year":"2024","journal-title":"Cells"},{"key":"B66","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41523-024-00625-7","article-title":"Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy","volume":"10","author":"Pascual","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"B67","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1038\/s41467-025-56279-x","article-title":"Cellular interactions within the immune microenvironment underpins resistance to cell cycle inhibition in breast cancers","volume":"16","author":"Griffiths","year":"2025","journal-title":"Nat Commun"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102544","article-title":"Molecular and cellular composition changes after neoadjuvant letrozole and palbociclib in early luminal breast cancer","volume":"7","author":"Cottu","year":"2026","journal-title":"Cell Rep Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-24-1158","article-title":"RANK pathway inhibition sensitizes triple-negative breast cancer to CDK4\/6 inhibitors and enhances immune response","volume":"24","author":"Gomes","year":"2025","journal-title":"Mol Cancer Ther"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1172\/JCI188839","article-title":"Dual targeting of CDK4\/6 and CDK7 augments tumor response and antitumor immunity in breast cancer models","volume":"135","author":"Kim","year":"2025","journal-title":"J Clin Invest"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-026-03786-w","article-title":"CSF1R inhibitors mitigate CDK4\/6 inhibitor-induced immunosuppression to increase antitumor immunity in HR+\/HER2-negative breast cancer","volume":"45","author":"Li","year":"2026","journal-title":"Oncogene"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-01007-z","article-title":"IL-17A-secreting \u03b3\u03b4 T cells promote resistance to CDK4\/CDK6 inhibitors in HR+HER2- breast cancer via CX3CR1+ macrophages","volume":"6","author":"Petroni","year":"2025","journal-title":"Nat Cancer"},{"key":"B73","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12929-025-01173-3","article-title":"CDK4\/6 inhibitors synergize with radiotherapy to prime the tumor microenvironment and enhance the antitumor effect of anti-PD-L1 immunotherapy in triple-negative breast cancer","volume":"32","author":"Yang","year":"2025","journal-title":"J BioMed Sci"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006019","article-title":"Dendritic cell therapy augments antitumor immunity triggered by CDK4\/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses","volume":"11","author":"Kumar","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102092","article-title":"Radiosensitizing effects of CDK4\/6 inhibitors in hormone receptor-positive and HER2-negative breast cancer mediated downregulation of DNA repair mechanism and NF-kB-signaling pathway","volume":"49","author":"Yang","year":"2024","journal-title":"Transl Oncol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/s41467-018-03215-x","article-title":"Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer","volume":"9","author":"O'Leary","year":"2018","journal-title":"Nat Commun"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03415-7","article-title":"Pembrolizumab and chemotherapy in high-risk, early-stage, ER+\/HER2- breast cancer: a randomized phase 3 trial","volume":"31","author":"Cardoso","year":"2025","journal-title":"Nat Med"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03414-8","article-title":"Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial","volume":"31","author":"Loi","year":"2025","journal-title":"Nat Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.6650","article-title":"Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial","volume":"6","author":"Nanda","year":"2020","journal-title":"JAMA Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0754","article-title":"MONARCH 1, a phase II study of abemaciclib as a single agent in patients with refractory HR+\/HER2-negative metastatic breast cancer","volume":"23","author":"Dickler","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2023.103580","article-title":"Neoadjuvant nivolumab plus palbociclib plus anastrozole for oestrogen receptor-positive\/human epidermal growth factor receptor 2-negative primary breast cancer: results from CheckMate 7A8","volume":"72","author":"Jerusalem","year":"2023","journal-title":"Breast"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01940","article-title":"PACE: A randomized phase II study of fulvestrant, palbociclib, and avelumab after progression on cyclin-dependent kinase 4\/6 inhibitor and aromatase inhibitor for hormone receptor-positive\/human epidermal growth factor receptor-negative metastatic breast cancer","volume":"42","author":"Mayer","year":"2024","journal-title":"J Clin Oncol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70426","article-title":"Immune-based transcriptomic signature predicts CDK4\/6 inhibitor efficacy in HR+\/HER2-negative breast cancer","volume":"15","author":"Felip","year":"2025","journal-title":"Clin Transl Med"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1235936","article-title":"Cellular RNA and DNA sensing pathways are essential for the dose-dependent response of human monocytes to ionizing radiation","volume":"14","author":"Mikhalkevich","year":"2023","journal-title":"Front Immunol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30060415","article-title":"Safety of CDK4\/6 inhibitors combined with radiotherapy in patients with metastatic breast cancer: a review of the literature","volume":"30","author":"Franco","year":"2023","journal-title":"Curr Oncol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3389\/pore.2023.1611369","article-title":"A new perspective on the proper timing of radiotherapy during CDK4\/6 inhibitor therapy in patients with \"bone-only\" metastatic breast cancer","volume":"29","author":"Tornyi","year":"2023","journal-title":"Pathol Oncol Res"},{"key":"B87","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ctro.2020.11.010","article-title":"CDK 4\/6 inhibitors combined with radiotherapy: a review of literature","volume":"26","author":"Bosacki","year":"2021","journal-title":"Clin Transl Radiat Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-2160","article-title":"Trastuzumab deruxtecan induces immunogenic cell death, immune cell activation and migration in viable human breast cancer slices [abstract","volume":"85","author":"Schulte","year":"2025","journal-title":"Cancer Res"},{"key":"B89","doi-asserted-by":"publisher","first-page":"11","DOI":"10.20517\/cdr.2024.180","article-title":"Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing","volume":"8","author":"Larose","year":"2025","journal-title":"Cancer Drug Resist"},{"key":"B90","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41523-025-00743-w","article-title":"Novel treatment approaches utilizing antibody-drug conjugates in breast cancer","volume":"11","author":"Davis","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2025.189369","article-title":"Sequencing of antibody drug conjugates in breast cancer: Evidence gap and future directions","volume":"1880","author":"Pacholczak-Madej","year":"2025","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101103","article-title":"Mechanisms of sensitivity and resistance to CDK4\/CDK6 inhibitors in hormone receptor-positive breast cancer treatment","volume":"76","author":"Glaviano","year":"2024","journal-title":"Drug Resist Update"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-021-00311-y","article-title":"Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer","volume":"7","author":"Spring","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2021.03.005","article-title":"A phase I\/Ib trial of PD 0332991 (Palbociclib) and T-DM1 in HER2-positive advanced breast cancer after trastuzumab and taxane therapy","volume":"21","author":"Haley","year":"2021","journal-title":"Clin Breast Cancer"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/1120009X.2025.2595811","article-title":"Efficacy and safety of trastuzumab deruxtecan in HER2-high and HER2-low breast cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"4","author":"Hsiao","year":"2025","journal-title":"J Chemother"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-00969-4","article-title":"p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2-positive breast cancer that limits trastuzumab deruxtecan efficacy","volume":"6","author":"Hu","year":"2025","journal-title":"Nat Cancer"},{"key":"B97","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1038\/s41467-020-16588-9","article-title":"Multiplexed relative and absolute quantitative immunopeptidomics reveals MHC I repertoire alterations induced by CDK4\/6 inhibition","volume":"11","author":"Stopfer","year":"2020","journal-title":"Nat Commun"},{"key":"B98","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s11427-021-2140-8","article-title":"Overexpressed cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4\/6 inhibitor in breast cancer that can be reversed by PI3K\/mTOR inhibitors","volume":"66","author":"Cai","year":"2023","journal-title":"Sci China Life Sci"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2177","article-title":"Genomic complexity predicts resistance to endocrine therapy and CDK4\/6 inhibition in hormone receptor-positive, HER2-negative metastatic breast cancer","volume":"29","author":"Davis","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-026-00986-1","article-title":"Real-world cell-free circulating tumor DNA analysis identifies CDK4\/6 inhibitor resistance and tumor evolution in HR+ advanced breast cancer","volume":"12","author":"Wander","year":"2026","journal-title":"NPJ Breast Cancer"},{"key":"B101","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1186\/s12967-025-06374-w","article-title":"Gene expression analysis in circulating tumour cells to determine resistance to CDK4\/6 inhibitors plus endocrine therapy in HR+\/HER2-negative metastatic breast cancer patients","volume":"23","author":"Gonz\u00e1lez-Conde","year":"2025","journal-title":"J Transl Med"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00215-7","article-title":"Serial single-cell genomics reveals convergent subclonal evolution of resistance as early-stage breast cancer patients progress on endocrine plus CDK4\/6 therapy","volume":"2","author":"Griffiths","year":"2021","journal-title":"Nat Cancer"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2024.2419352","article-title":"Using bioinformatics and artificial intelligence to map the cyclin-dependent kinase 4\/6 inhibitor biomarker landscape in breast cancer","volume":"20","author":"Wager","year":"2024","journal-title":"Future Oncol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2022.37","article-title":"Liquid biopsies to predict CDK4\/6 inhibitor efficacy and resistance in breast cancer","volume":"5","author":"Main","year":"2022","journal-title":"Cancer Drug Resist"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01323-8","article-title":"A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer","volume":"27","author":"Bassez","year":"2021","journal-title":"Nat Med"},{"key":"B106","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1038\/s41467-026-71452-6","article-title":"Neoadjuvant palbociclib and endocrine therapy versus chemotherapy in ER+\/HER2-negative breast cancer: a randomized phase II trial","volume":"17","author":"Matikas","year":"2026","journal-title":"Nat Commun"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001653","article-title":"MHC class I loss in triple-negative breast cancer: a potential barrier to PD-1\/PD-L1 checkpoint inhibitors","volume":"45","author":"Dusenbery","year":"2021","journal-title":"Am J Surg Pathol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1934879\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T05:44:50Z","timestamp":1787118290000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1934879\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":107,"alternative-id":["10.3389\/fimmu.2026.1934879"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1934879","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"article-number":"1934879"}}